Malta - Inggris - Medicines Authority

mylan s.a.s. 117 allee des parcs, 69800 saint priest, france - doxorubicin hydrochloride - concentrate for solution for infusion - doxorubicin hydrochloride 2 mg - antineoplastic agents

Kanada - Inggris - Health Canada

novopharm limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Kanada - Inggris - Health Canada

omega laboratories limited - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Kanada - Inggris - Health Canada

strides pharma canada inc - doxorubicin hydrochloride - solution - 2mg - doxorubicin hydrochloride 2mg - antineoplastic agents

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - doxorubicin hydrochloride, quantity: 50 mg - injection, powder for - excipient ingredients: methyl hydroxybenzoate; lactose - doxorubicin has been used successfully to produce regression in neoplastic conditions such as acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's types, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma. doxorubicin is also indicated by intravesical administration in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2).

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - doxorubicin hydrochloride, quantity: 10 mg - injection, powder for - excipient ingredients: lactose; methyl hydroxybenzoate - doxorubicin has been used successfully to produce regression in neoplastic conditions such as acute leukaemia, wilms' tumour, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, lymphomas of both hodgkin's and non-hodgkin's types, bronchogenic (lung) carcinoma, thyroid carcinoma, hepatomas and ovarian carcinoma. doxorubicin is also indicated by intravesical administration in the primary management of nonmetastatic carcinoma of the bladder (tis, t1, t2).

Amerika Serikat - Inggris - NLM (National Library of Medicine)

janssen products, lp - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - doxil is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. doxil is indicated for the treatment of aids-related kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. doxil, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy. doxil is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride [see warnings and precautions (5.2)]. risk summary based on findings in animals and its mechanism of action, doxil can cause fetal harm when administered to a pregnant woman; avoid the use of doxil during the 1st trimester. in animal reproduction studies, doxil was embryotoxic in rats and abortifacient in rabbits following intravenous administration during organogenesis at dos

Amerika Serikat - Inggris - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - doxorubicin hydrochloride (unii: 82f2g7bl4e) (doxorubicin - unii:80168379ag) - doxorubicin hydrochloride 2 mg in 1 ml - adriamycin (doxorubicin hcl) for injection, usp is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer [see clinical studies (14.1)]. doxorubicin is indicated for the treatment of - acute lymphoblastic leukemia - acute myeloblastic leukemia - hodgkin lymphoma - non-hodgkin lymphoma (nhl) - metastatic breast cancer - metastatic wilms’ tumor - metastatic neuroblastoma - metastatic soft tissue sarcoma - metastatic bone sarcoma - metastatic ovarian carcinoma doxorubicin is contraindicated in patients with: - severe myocardial insufficiency [see warnings and precautions (5.1)] - recent (occurring within the past 4 to 6 weeks) myocardial infarction [see warnings and precautions (5.1)] - severe persistent drug-induced myelosuppression [see warnings and precautions (5.4)] severe hepatic impairment (defined as child pugh class c or serum bilirubin level greater than 5 mg/dl) [see warnings and precautions

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: hydrogenated soy phosphatidylcholine; histidine; hydrochloric acid; ammonium sulfate; cholesterol; water for injections; sodium hydroxide; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose - indications: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: ammonium sulfate; histidine; water for injections; sodium hydroxide; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose; hydrogenated soy phosphatidylcholine; hydrochloric acid - for the treatment of aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm) and extensive mucocutaneous or visceral disease. caelyx may be used for first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 21 september 2001: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.